Notes
2015 US dollars
Reference
Salazar J, et al. Cost-Effectiveness of Direct-Acting Anti-viral Treatment in Hepatitis C-infected Liver Transplant Candidates with Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation : 6 Dec 2016. Available from: URL: http://doi.org/10.1097/TP.0000000000001605
Rights and permissions
About this article
Cite this article
Deferring DDAs until after liver transplant cost effective. PharmacoEcon Outcomes News 769, 9 (2017). https://doi.org/10.1007/s40274-017-3645-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3645-0